EGFR and non-small cell lung carcinoma: Another potent third-generation EGFR-TKI, lazertinib, was also proven to provide a median PFS that is significantly longer than gefitinib [20.6 months versus 9.7 months; HR of 0.45 (95% CI, 0.34 to 0.58); p < 0.001] in first-line treatment for EGFR-mutated advanced NSCLC patients [21].